Clinical Trial Update: Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluates differentiation therapy with decitabine in patients with myelodysplastic syndromes and related conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-02-26